IA Trial Radar | ||
|---|---|---|
El ensayo clínico NCT07431281 para Cáncer gástrico, Adenocarcinoma de la Unión Gastroesofágica, Cáncer de esófago está reclutando. Consulte la vista de tarjeta del Radar de Ensayos Clínicos y las herramientas de descubrimiento de IA para conocer todos los detalles. O haga cualquier pregunta aquí. | ||
Un estudio coincide con los criterios de filtro
Vista de tarjeta
Volver a la búsqueda
AstraZenecaSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 Fase III 2130
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el estudio' para ver y discutir la información del estudio en el idioma que haya seleccionado.
El ensayo clínico NCT07431281 está diseñado para estudiar el tratamiento de Cáncer gástrico, Adenocarcinoma de la Unión Gastroesofágica, Cáncer de esófago. Es un estudio intervencionista de Fase III. Su estado actual es: reclutando. El estudio se inició el 3 de febrero de 2026, con el objetivo de reclutar a 2130 participantes. Dirigido por AstraZeneca, se espera que finalice el 27 de octubre de 2031. Los datos se actualizaron por última vez en ClinicalTrials.gov el 24 de febrero de 2026.
Resumen
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Descripción detallada
The purpose of this Phase III study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in 1L CLDN18.2-positive, HER2-negative gastric, GEJ, and esophageal adenocarcinoma, and the clinical performance of the investigation in vitro diagnostics (IVDs). The study will include 2 cohorts to provide a treatment option for all participants that are HER...Mostrar más
Título oficial
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
Condiciones médicas
Cáncer gástricoAdenocarcinoma de la Unión GastroesofágicaCáncer de esófagoOtros ID del estudio
- D9803C00001
- 2024-519787-40-00 (Identificador de registro) (Clinical Trials Information System (CTIS))
Número del NCT
Inicio del estudio (real)
2026-02-03
Última actualización
2026-02-24
Fecha de finalización (estimada)
2031-10-27
Inscripción (prevista)
2130
Tipo de estudio
Intervencionista
FASE
Fase III
Estado general
Reclutando
Palabras clave
Advanced Gastroesophageal Junction (GEJ) Adenocarcinoma,
Advanced Gastric Adenocarcinoma,
Advanced Esophageal Adenocarcinoma,
Metastatic Gastric Adenocarcinoma,
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,
Metastatic Esophageal Adenocarcinoma,
Claudin 18.2,
PD-L1,
Human epidermal growth factor receptor 2 (HER2) Negative
Advanced Gastric Adenocarcinoma,
Advanced Esophageal Adenocarcinoma,
Metastatic Gastric Adenocarcinoma,
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,
Metastatic Esophageal Adenocarcinoma,
Claudin 18.2,
PD-L1,
Human epidermal growth factor receptor 2 (HER2) Negative
Objetivo principal
Tratamiento
Método de asignación
Aleatorizado
Modelo de intervención
Paralelo
Enmascaramiento
Simple ciego
Brazos / Intervenciones
| Grupo de participantes | Intervención/Tratamiento |
|---|---|
ExperimentalArm A Sonesitatug vedotin + Rilvegostomig + Capecitabine | Sonesitatug vedotin Intravenous Rilvegostomig Intravenous Capecitabine Oral |
ExperimentalArm B Sonesitatug vedotin + Nivolumab + Capecitabine | Sonesitatug vedotin Intravenous Nivolumab Intravenous Capecitabine Oral |
Comparador activoArm C Nivolumab + CAPOX OR Nivolumab + FOLFOX
* nivolumab, capecitabine, oxaliplatin
* nivolumab, 5-Fluorouracil, leucovorin, oxaliplatin | Nivolumab Intravenous Capecitabine Oral 5-Fluorouracil Intravenous Oxaliplatin Intravenous Leucovorin Intravenous |
ExperimentalArm D Sonesitatug vedotin + Capecitabine | Sonesitatug vedotin Intravenous Capecitabine Oral |
Comparador activoArm E Zolbetuximab + CAPOX or Zolbetuximab + FOLFOX:
* zolbetuximab, capecitabine, oxaliplatin
* zolbetuximab, 5-Fluorouracil, leucovorin, oxaliplatin
CAPOX or FOLFOX:
* oxaliplatin, capecitabine,
* 5-Fluorouracil, leucovorin, oxaliplatin | Capecitabine Oral 5-Fluorouracil Intravenous Oxaliplatin Intravenous Zolbetuximab Intravenous Leucovorin Intravenous |
Resultado primario
Resultado secundario
| Medida de resultado | Descripción de la medida | Periodo de tiempo |
|---|---|---|
Progression Free Survival (PFS) (Cohort 1 and Cohort 2) | PFS is defined as time from randomisation until progression per RECIST 1.1, or death due to any cause, whichever occurs first. | Up to approximately 5 years |
Overall Survival (OS) (Cohort 1) | OS is defined as the time from randomisation until the date of death due to any cause. | Up to approximately 5 years |
| Medida de resultado | Descripción de la medida | Periodo de tiempo |
|---|---|---|
Overall Survival (OS) (Cohort 2) | OS is defined as the time from randomisation until the date of death due to any cause. | Up to approximately 5 years |
Overall Survival (OS) (Cohort 1) | OS is defined as time from randomisation until date of death due to any cause. Arm B versus C. | Up to approximately 5 years |
Progression Free Survival (PFS) (Cohort 1) | PFS is defined as time from randomisation until progression per RECIST 1.1 or death due to any cause, whichever occurs first. Arms B versus C. | Up to approximately 5 years |
Objective Response Rate (ORR) (Cohort 1 and Cohort 2) | ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, per RECIST 1.1. | Up to approximately 5 years |
Duration of Response (DoR) (Cohort 1 and Cohort 2) | DoR (per RECIST 1.1) is derived for confirmed objective responses (CR or PR) only and is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression (ie, date of PFS event - date of first response + 1). | Up to approximately 5 years |
Pharmacokinetics of sonesitatug vedotin (Cohort 1 and Cohort 2) | Pharmacokinetic parameters of sonesitatug vedotin (peak plasma concentration (Cmax)) | Up to approximately 5 years |
Pharmacokinetics of sonesitatug vedotin (Cohort 1 and Cohort 2) | Pharmacokinetic parameters of sonesitatug vedotin (trough plasma concentration (Cmin)) | Up to approximately 5 years |
Immunogenicity of sonesitatug vedotin (Cohort 1 and Cohort 2) | Presence of ADAs for sonesitatug vedotin in serum (confirmatory results: positive or negative, titres). | Up to approximately 5 years |
Pharmacokinetics of rilvegostomig (Cohort 1) | Pharmacokinetic parameters of rilvegostomig (peak plasma concentration (Cmax)) | Up to approximately 5 years |
Pharmacokinetics of rilvegostomig (Cohort 1) | Pharmacokinetic parameters of rilvegostomig (trough plasma concentration (Cmin)) | Up to approximately 5 years |
Immunogenicity of rilvegostomig (Cohort 1) | Presence of ADAs for rilvegostomig in serum (confirmatory results: positive or negative, titres). | Up to approximately 5 years |
Safety and tolerability (Cohort 1 and Cohort 2) | Safety and tolerability as evaluated in terms of incidence of AEs and SAEs | Up to approximately 5 years |
Asistente de participación
Criterios de elegibilidad
Criterios de edad
Adulto, Adulto mayor
Edad mínima
18 Years
Criterios de sexo
Todos
Capable of giving signed informed consent
Participant must be 18 years or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
Previously untreated histologically documented unresectable, locally advanced, or metastatic gastric, GEJ, or distal esophagus (distal third of the esophagus) adenocarcinoma
Positive CLDN18.2 expression, as determined prospectively by central IHC testing
Confirmed PD-L1 CPS status by central IHC testing and ICI eligibility per investigator judgement is required to determine cohort eligibility as described below:
- Cohort 1: PD-L1 positive as determined by central IHC testing and the participant is deemed ICI eligible per investigator judgement.
- Cohort 2: PD-L1 negative as determined by central IHC testing OR the participant is ICI ineligible
ECOG performance status of 0 or 1 with no deterioration to > 1 over the previous 2 weeks prior to baseline at screening and prior to randomisation.
Minimum life expectancy of ≥ 12 weeks.
At least one lesion (measurable and/or non-measurable) that can be accurately assessed by the investigator based on RECIST 1.1.
Adequate organ and bone marrow function as specified in the protocol
Body weight ≥ 35 kg.
Sex and contraceptive requirements
- Known HER2-positive status
- Significant or unstable gastric bleeding and/or untreated gastric ulcers.
- Active or history of autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment or assessed by investigator as not appropriate to participate due to undue risk are excluded.
- CNS pathology
- Clinically significant pleural effusions or ascites and/or pleural effusions or ascites that require drainage, peritoneal shunt, or indwelling catheter/drain.
- Require parenteral nutrition support due to gastric or gastrointestinal obstruction.
- Peripheral neuropathy, sensory or motor, ≥ CTCAE Grade 2 at screening.
- Persistent toxicities caused by previous anticancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
- Cardiac abnormalities as outlined in the protocol
- Uncontrolled diabetes or diabetic neuropathy within 3 months prior to randomisation.
- Infectious disease including active hepatitis A infection; uncontrolled hepatitis B and/or chronic or active hepatitis B with HBV DNA ≥ 100 IU/mL; Known chronic, active, or uncontrolled hepatitis C; HIV infection that is not well controlled
- Known partial or total DPD enzyme deficiency
AstraZenecaContactos centrales del estudio
Contacto: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
230 Centros del estudio en 20 países
Research Site, Barcelona, 08035, Spain
Aún no recluta
Research Site, Barcelona, 8036, Spain
Aún no recluta
Research Site, Madrid, 28041, Spain
Aún no recluta
Research Site, Pamplona, 31008, Spain
Aún no recluta
Research Site, Santander, 39008, Spain
Aún no recluta
Research Site, Santiago de Compostela, 15706, Spain
Aún no recluta
Research Site, Valencia, 46010, Spain
Aún no recluta
Research Site, San Juan, 00921, Puerto Rico
Aún no recluta
Arizona
Research Site, Phoenix, Arizona, 85054, United States
Aún no recluta
California
Research Site, Duarte, California, 91010, United States
Aún no recluta
Research Site, La Jolla, California, 92093, United States
Aún no recluta
Research Site, Orange, California, 92868, United States
Aún no recluta
Research Site, Walnut Creek, California, 94598, United States
Aún no recluta
Colorado
Research Site, Lone Tree, Colorado, 80124, United States
Aún no recluta
Connecticut
Research Site, New Haven, Connecticut, 06510, United States
Retirado
Delaware
Research Site, Newark, Delaware, 19713, United States
Aún no recluta
District of Columbia
Research Site, Washington D.C., District of Columbia, 20007, United States
Retirado
Florida
Research Site, Fort Myers, Florida, 33901, United States
Aún no recluta
Research Site, Jacksonville, Florida, 32224, United States
Aún no recluta
Research Site, St. Petersburg, Florida, 33705, United States
Aún no recluta
Research Site, West Palm Beach, Florida, 33401, United States
Aún no recluta
Georgia
Research Site, Atlanta, Georgia, 30309, United States
Aún no recluta
Research Site, Atlanta, Georgia, 30322, United States
Aún no recluta
Research Site, Atlanta, Georgia, 30342, United States
Retirado
Illinois
Research Site, Chicago, Illinois, 60637, United States
Aún no recluta
Research Site, Niles, Illinois, 60714, United States
Aún no recluta
Kentucky
Research Site, Lexington, Kentucky, 40536, United States
Aún no recluta
Research Site, Louisville, Kentucky, 40207, United States
Aún no recluta
Massachusetts
Research Site, Boston, Massachusetts, 02114, United States
Aún no recluta
Michigan
Research Site, Grand Rapids, Michigan, 49503, United States
Aún no recluta
Minnesota
Research Site, Burnsville, Minnesota, 55337, United States
Aún no recluta
Research Site, Rochester, Minnesota, 55905, United States
Aún no recluta
Missouri
Research Site, Kansas City, Missouri, 64132, United States
Aún no recluta
Research Site, St Louis, Missouri, 63110, United States
Aún no recluta
New Jersey
Research Site, East Brunswick, New Jersey, 08816, United States
Aún no recluta
Research Site, Hackensack, New Jersey, 07601, United States
Aún no recluta
Research Site, Summit, New Jersey, 07901, United States
Aún no recluta
New York
Research Site, New York, New York, 10029, United States
Aún no recluta
Research Site, New York, New York, 10032, United States
Aún no recluta
Research Site, New York, New York, 10065, United States
Aún no recluta
Research Site, The Bronx, New York, 10461, United States
Aún no recluta
Research Site, The Bronx, New York, 10468, United States
Aún no recluta
Research Site, White Plains, New York, 10601, United States
Retirado
North Carolina
Research Site, Winston-Salem, North Carolina, 27103, United States
Aún no recluta
Ohio
Research Site, Cleveland, Ohio, 44195, United States
Retirado
Research Site, Columbus, Ohio, 43221, United States
Aún no recluta
Oregon
Research Site, Portland, Oregon, 97213, United States
Aún no recluta
Research Site, Portland, Oregon, 97239, United States
Aún no recluta
Pennsylvania
Research Site, Hershey, Pennsylvania, 17033, United States
Aún no recluta
Research Site, Philadelphia, Pennsylvania, 19104, United States
Aún no recluta
Research Site, Pittsburgh, Pennsylvania, 15232, United States
Aún no recluta
Research Site, Pittsburgh, Pennsylvania, 15240, United States
Aún no recluta
Research Site, Wilkes-Barre, Pennsylvania, 18711, United States
Aún no recluta
South Dakota
Research Site, Sioux Falls, South Dakota, 57105, United States
Aún no recluta
Tennessee
Research Site, Memphis, Tennessee, 38104, United States
Aún no recluta
Research Site, Nashville, Tennessee, 37203, United States
Aún no recluta
Texas
Research Site, Dallas, Texas, 75246, United States
Aún no recluta
Research Site, Sherman, Texas, 75090, United States
Aún no recluta
Virginia
Research Site, Blacksburg, Virginia, 24060, United States
Aún no recluta
Research Site, Fairfax, Virginia, 22031, United States
Aún no recluta
Research Site, Falls Church, Virginia, 22042, United States
Retirado
Research Site, Fort Belvoir, Virginia, 22060, United States
Aún no recluta
Research Site, Richmond, Virginia, 23219, United States
Aún no recluta
Washington
Research Site, Seattle, Washington, 98104, United States
Aún no recluta
West Virginia
Research Site, Charleston, West Virginia, 25315, United States
Aún no recluta
Research Site, Darlinghurst, 2010, Australia
Suspendido
Research Site, Garran, 2605, Australia
Aún no recluta
Research Site, Heidelberg, 3084, Australia
Aún no recluta
Research Site, Murdoch, 6150, Australia
Aún no recluta
Research Site, Randwick, 2031, Australia
Aún no recluta
Research Site, Westmead, 2145, Australia
Aún no recluta
Research Site, Linz, 4010, Austria
Retirado
Research Site, Rankweil, 6830, Austria
Retirado
Research Site, Vienna, 1090, Austria
Retirado
Research Site, Wiener Neustadt, 2700, Austria
Retirado
Research Site, Brussels, 1200, Belgium
Aún no recluta
Research Site, Edegem, 2650, Belgium
Aún no recluta
Research Site, Ghent, 9000, Belgium
Aún no recluta
Research Site, Leuven, 3000, Belgium
Aún no recluta
Research Site, Barretos, 14784-400, Brazil
Aún no recluta
Research Site, Fortaleza, 60336-045, Brazil
Aún no recluta
Research Site, Natal, 59075-740, Brazil
Aún no recluta
Research Site, Porto Alegre, 91350200, Brazil
Aún no recluta
Research Site, Salvador, 41.950-610, Brazil
Aún no recluta
Research Site, Santa Maria, 97015-450, Brazil
Aún no recluta
Research Site, São Paulo, 01246-000, Brazil
Aún no recluta
Research Site, Vitória, 29043-260, Brazil
Aún no recluta
Alberta
Research Site, Edmonton, Alberta, T6G 1Z2, Canada
Aún no recluta
British Columbia
Research Site, Abbotsford British Columbia, British Columbia, V2S0C2, Canada
Aún no recluta
Research Site, Vancouver, British Columbia, VSZ 4E6, Canada
Aún no recluta
Manitoba
Research Site, Winnipeg, Manitoba, R3E 0V9, Canada
Aún no recluta
Ontario
Research Site, Brampton, Ontario, L6R 3J7, Canada
Aún no recluta
Research Site, Ottawa, Ontario, K1H 8L6, Canada
Aún no recluta
Research Site, Toronto, Ontario, M4N 3M5, Canada
Aún no recluta
Research Site, Toronto, Ontario, M5G 2M9, Canada
Aún no recluta
Quebec
Research Site, Montreal, Quebec, H3A 1A1, Canada
Reclutando
Research Site, Québec, Quebec, G1J 1Z4, Canada
Aún no recluta
Research Site, Beijing, 100032, China
Aún no recluta
Research Site, Beijing, 100050, China
Aún no recluta
Research Site, Beijing, 100142, China
Aún no recluta
Research Site, Beijing, 102200, China
Aún no recluta
Research Site, Changde, 415000, China
Aún no recluta
Research Site, Chengdu, 610041, China
Aún no recluta
Research Site, Chongqing, 400016, China
Aún no recluta
Research Site, Fuzhou, 350005, China
Aún no recluta
Research Site, Fuzhou, 350011, China
Aún no recluta
Research Site, Guangzhou, 510655, China
Aún no recluta
Research Site, Hangzhou, 310003, China
Aún no recluta
Research Site, Hangzhou, 310014, China
Aún no recluta
Research Site, Hangzhou, 310020, China
Aún no recluta
Research Site, Harbin, 150081, China
Aún no recluta
Research Site, Hefei, 230031, China
Aún no recluta
Research Site, Hohhot, 010020, China
Aún no recluta
Research Site, Jinan, 2501117, China
Aún no recluta
Research Site, Kunming, 650118, China
Aún no recluta
Research Site, Lanzhou, 730000, China
Aún no recluta
Research Site, Linhai, 317000, China
Aún no recluta
Research Site, Linyi, 276000, China
Aún no recluta
Research Site, Nanchang, 330000, China
Aún no recluta
Research Site, Nanchang, 330029, China
Aún no recluta
Research Site, Nanjing, 2100008, China
Aún no recluta
Research Site, Nanjing, 210029, China
Aún no recluta
Research Site, Nanning, 530021, China
Aún no recluta
Research Site, Nantong, 226361, China
Aún no recluta
Research Site, Shanghai, 200025, China
Aún no recluta
Research Site, Shanghai, 200127, China
Aún no recluta
Research Site, Shanghai, 20032, China
Aún no recluta
Research Site, Shantou, 515041, China
Aún no recluta
Research Site, Shenyang, 110016, China
Aún no recluta
Research Site, Shenzhen, 518036, China
Aún no recluta
Research Site, Tianjin, 300050, China
Aún no recluta
Research Site, Wuhan, 430030, China
Aún no recluta
Research Site, Wuhan, 430079, China
Aún no recluta
Research Site, Xi'an, 710068, China
Aún no recluta
Research Site, Xiamen, 361003, China
Aún no recluta
Research Site, Xingtai, 054031, China
Aún no recluta
Research Site, Xuzhou, 221009, China
Aún no recluta
Research Site, Yinchuan, 750004, China
Aún no recluta
Research Site, Zhengzhou, 450008, China
Aún no recluta
Research Site, Augsburg, 86156, Germany
Aún no recluta
Research Site, Berlin, 13353, Germany
Aún no recluta
Research Site, Bonn, 53127, Germany
Aún no recluta
Research Site, Essen, 45122, Germany
Aún no recluta
Research Site, Frankfurt, 60488, Germany
Aún no recluta
Research Site, Freiburg im Breisgau, 79106, Germany
Aún no recluta
Research Site, Hamburg, 20249, Germany
Aún no recluta
Research Site, Heidelberg, 69120, Germany
Retirado
Research Site, Heilbronn, 74078, Germany
Aún no recluta
Research Site, Leipzig, 04103, Germany
Aún no recluta
Research Site, Mainz, 55131, Germany
Aún no recluta
Research Site, Mannheim, 68167, Germany
Retirado
Research Site, Moers, 47441, Germany
Aún no recluta
Research Site, München, 81657, Germany
Aún no recluta
Research Site, Stuttgart, 70376, Germany
Aún no recluta
Research Site, Ulm, 89081, Germany
Aún no recluta
Research Site, Budapest, 1083, Hungary
Aún no recluta
Research Site, Budapest, 1122, Hungary
Aún no recluta
Research Site, Debrecen, 4032, Hungary
Aún no recluta
Research Site, Győr, 9024, Hungary
Aún no recluta
Research Site, Gyula, 5700, Hungary
Aún no recluta
Research Site, Nyíregyháza, 4400, Hungary
Aún no recluta
Research Site, Pécs, 7624, Hungary
Aún no recluta
Research Site, Zalaegerszeg, 8900, Hungary
Aún no recluta
Research Site, Ahmedabad, 380060, India
Aún no recluta
Research Site, Bhubaneshwar, 751019, India
Aún no recluta
Research Site, Hyderabad, 500032, India
Aún no recluta
Research Site, Mohali, 160055, India
Aún no recluta
Research Site, Mumbai, 400012, India
Aún no recluta
Research Site, New Delhi, 110017, India
Aún no recluta
Research Site, New Delhi, 110060, India
Aún no recluta
Research Site, Varanasi, 221005, India
Retirado
Research Site, Vijayawada, 520002, India
Aún no recluta
Research Site, Meldola, 47014, Italy
Aún no recluta
Research Site, Milan, 20133, Italy
Aún no recluta
Research Site, Milan, 20141, Italy
Aún no recluta
Research Site, Milan, 20162, Italy
Aún no recluta
Research Site, Padua, 35128, Italy
Aún no recluta
Research Site, Rozzano, 20089, Italy
Aún no recluta
Research Site, Tricase, 73039, Italy
Aún no recluta
Research Site, Hirakata-shi, 573-1191, Japan
Aún no recluta
Research Site, Kashiwa, 277-8577, Japan
Aún no recluta
Research Site, Kitaadachi-gun, 362-0806, Japan
Aún no recluta
Research Site, Kōtoku, 135-8550, Japan
Aún no recluta
Research Site, Kurashiki-shi, 710-8602, Japan
Aún no recluta
Research Site, Niigata, 951-8566, Japan
Aún no recluta
Research Site, Osaka, 541-8567, Japan
Aún no recluta
Research Site, Sakai, 590-0197, Japan
Aún no recluta
Research Site, Sunto-gun, 411-8777, Japan
Aún no recluta
Research Site, Yokohama, 232-0024, Japan
Aún no recluta
Research Site, Gdansk, 80-219, Poland
Aún no recluta
Research Site, Koszalin, 75-581, Poland
Aún no recluta
Research Site, Krakow, 31-501, Poland
Aún no recluta
Research Site, Lublin, 20-080, Poland
Aún no recluta
Research Site, Olsztyn, 10-228, Poland
Aún no recluta
Research Site, Warsaw, 02-034, Poland
Aún no recluta
Research Site, Daegu, 41404, South Korea
Aún no recluta
Research Site, Hwasun-gun, 58128, South Korea
Aún no recluta
Research Site, Seongnam-si, 13620, South Korea
Aún no recluta
Research Site, Seoul, 03080, South Korea
Aún no recluta
Research Site, Seoul, 03722, South Korea
Aún no recluta
Research Site, Seoul, 05505, South Korea
Aún no recluta
Research Site, Seoul, 06351, South Korea
Aún no recluta
Research Site, Seoul, 06591, South Korea
Aún no recluta
Research Site, Kaohsiung City, 80756, Taiwan
Reclutando
Research Site, Kaohsiung City, 83301, Taiwan
Aún no recluta
Research Site, Taichung, 40447, Taiwan
Reclutando
Research Site, Taichung, Taiwan
Aún no recluta
Research Site, Tainan, 704, Taiwan
Aún no recluta
Research Site, Taipei, 10002, Taiwan
Aún no recluta
Research Site, Taipei, 112, Taiwan
Aún no recluta
Research Site, Taoyuan District, 333, Taiwan
Aún no recluta
Research Site, Bangkok, 10210, Thailand
Aún no recluta
Research Site, Bangkok, 10700, Thailand
Aún no recluta
Research Site, Dusit, 10300, Thailand
Aún no recluta
Research Site, Hat Yai, 90110, Thailand
Aún no recluta
Research Site, Khon Kaen, 40002, Thailand
Aún no recluta
Research Site, Muang, 22000, Thailand
Aún no recluta
Research Site, Muang, 70000, Thailand
Aún no recluta
Research Site, Ankara, 06530, Turkey (Türkiye)
Aún no recluta
Research Site, Antalya, 07100, Turkey (Türkiye)
Aún no recluta
Research Site, Istanbul, 34098, Turkey (Türkiye)
Aún no recluta
Research Site, Istanbul, 34854, Turkey (Türkiye)
Aún no recluta
Research Site, Medreseboğazı, 01250, Turkey (Türkiye)
Aún no recluta
Research Site, Şahinbey, 27310, Turkey (Türkiye)
Aún no recluta
Research Site, Cambridge, CB2 0QQ, United Kingdom
Aún no recluta
Research Site, Dundee, DD1 9SY, United Kingdom
Aún no recluta
Research Site, Leeds, LS9 7TF, United Kingdom
Aún no recluta
Research Site, London, EC1A 7BE, United Kingdom
Aún no recluta
Research Site, Manchester, M20 4BX, United Kingdom
Aún no recluta
Research Site, Oxford, OX3 7LE, United Kingdom
Aún no recluta